SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| TIMOTHY CLARK | — |
| MARYANNE DOLBEARE DUNLAP | — |
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
Torts TOR
General issues related to efforts to reform the Vaccine Injury Compensation Program.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
Medicare/Medicaid MMM
Issues related to changing reimbursement for physicians the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| TIMOTHY CLARK | — |
| MARYANNE DOLBEARE DUNLAP | — |
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
Taxation/Internal Revenue Code TAX
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)"
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
| ANN TAYLOR | — |
Copyright/Patent/Trademark CPT
HR 1249 "America Invents Act" provisions related to first to file, inter parties review and supplemental re-examination; issues related to patent settlements, including such provisions in S 27 "Preserve Access to Affordable Generics Act"; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements; international intellectual property issues
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| TIMOTHY CLARK | — |
| EDDIE D EVANS | — |
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
Health Issues HCR
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR2529 "Restoring Access to Medication Act", the Medication Therapy Management Program, and the Independent Payment Advisory Board (IPAB); awareness and issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S Res 243 "A resolution promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act".
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
| Lobbyist | Covered position, as disclosed |
|---|---|
| SEAN CALLINICOS | — |
| TIMOTHY CLARK | — |
| MARYANNE DOLBEARE DUNLAP | — |
| EDWARD GREISSING | — |
| PATRICK MAYES MCLAIN | — |
| AMY L REDL | — |
| ANN TAYLOR | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.